​In modern oncology, genomic testing has become an essential component of metastatic breast cancer (mBC) management, directly influencing treatment selection, sequencing, and clinical trial enrollment. However, a significant global variance persists in how these complex genomic tests are selected, interpreted, and applied in routine clinical practice. Beyond technical execution, genomic results deeply impact a patient’s understanding of their disease, creating an urgent need for healthcare providers to deliver clear, empathetic, and patient-centered communication.
​To bridge these distinct gaps, Pfizer Global Medical Grants has issued a Request for Proposals (RFP) for its Independent Medical Education (IME) Competitive Grant Program. This initiative aims to fund comprehensive educational programs that simultaneously strengthen healthcare professional (HCP) genomic competence and enhance patient-centered shared decision-making in mBC care.
​Quick Summary Box
| Feature | Details |
|---|---|
| Sponsoring Body | Pfizer International LLC (administered via Pfizer Global Medical Grants) |
| Program Title | Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer |
| Primary Area of Interest | Oncology - Breast - IME |
| Funding Amount | Up to $100,000.00 USD per project (smaller requests around $35,000.00 are also encouraged) |
| Maximum Project Length | 18 months |
| Total Grants Available | Up to 10 selected studies (national or multi-country) will be funded |
| Upcoming Submission Deadline | July 20, 2026, at 23:59 Eastern Standard Time (EST) |
Opportunity Overview
​This competitive grant program seeks independent medical education activities designed to improve routine mBC management. Reviewers are looking for integrated educational curricula that address two primary pillars: building HCP genomic competence and strengthening patient-centered communication skills.
​Programs should address the practical difficulties clinicians face when translating complex biological reports into plain-language discussions that incorporate patient values and preferences. Funded projects must focus purely on independent medical education; clinical research evaluating the efficacy of therapeutic/diagnostic agents or general quality improvement (QI) initiatives are strictly out of scope.
​Benefits
- ​Substantial Financial Support: Individual projects can receive up to $100,000.00 USD in total funding to support design, development, and execution costs.
- ​Overhead Coverage: Award amounts include direct costs, indirect costs, and institutional overhead costs, with overhead capped at a generous 28% per Pfizer policy.
- ​Global Academic Impact: Programs have the opportunity to establish standardized, unbranded genomic education tools that can be shared broadly across multi-disciplinary oncology teams.
​Eligibility Criteria
- ​Organizational Eligibility: Only registered organizations may apply. Eligible entities include medical, nursing, allied health, and pharmacy professional schools; healthcare institutions (large and small); professional organizations/medical societies; and medical education companies. Individuals and independent medical practice groups unaffiliated with an academic institution or hospital are ineligible.
- ​Leadership Requirements: The applicant must be the program lead or an authorized designee (e.g., a grant coordinator). The primary program lead must be a direct employee or contractor of the requesting organization.
- ​Accreditation: If the proposed project offers continuing education (CE) credits, the requesting organization must hold valid accreditation.
- ​Multi-Departmental Collaborations: If a project spans multiple departments or separate institutions, all parties must have an active, defined role, and the primary requesting organization must maintain a key role throughout.
​Eligible Healthcare Professions
​The target educational audience for proposed projects must comprise:
- ​Medical and clinical oncologists
- ​Breast cancer specialists actively treating metastatic disease
- ​Relevant multidisciplinary team members involved in selecting, tracking, or interpreting genomic testing (such as oncology nurses, molecular pathologists, and clinical pharmacists).
​IMG/International Applicant Considerations
​The geographic scope of this RFP is strictly international, limited to organizations operating within the following countries:
- ​Canada, China, France, Germany, India, Italy, Japan, Spain, and the United Kingdom.
​Country-Specific Rules:
- ​India: Requesting Indian institutions must possess a valid, active Foreign Contribution Regulation Act (FCRA) certificate spanning the entire duration of the grant to legally receive foreign funding.
- ​Italy: Educazione Continua in Medicina (ECM) events are explicitly excluded from support. Only non-ECM initiatives will be evaluated for Italian applicants.
- ​Funding Disbursal: This grant is supported by Pfizer International LLC, and approved payments will be legally issued via a US-based Pfizer entity directly to the grantee organization.
​Required Documents
​Project proposals must be uploaded via the online portal and must be single-spaced using Calibri 12-point font with 1-inch margins. There is a strict 15-page limit exclusive of references. The uploaded proposal must address the following structural modules:
- ​Goals and Objectives: Statement of the overall project goal and specific learning outcomes.
- ​Assessment of Need: A thorough, data-driven gap analysis utilizing baseline metrics or patient-level data to justify the educational intervention.
- ​Target Audience Details: Description of the primary audience, estimated total population size, and expected sample size.
- ​Project Design and Methods: Detailed breakdown of the educational format and teaching methodologies.
- ​Innovation: Explanation of project originality, ensuring it does not duplicate existing public materials and builds cleanly on previous work.
- ​Evaluation and Outcomes: Clear plan for how the organization will track data, control for external factors (e.g., using a control group or baseline comparisons), and measure target audience engagement.
- ​Dissemination Plan: Strategy for making tools, resources, or teaching materials publicly available beyond the lifespan of the grant.
- ​Anticipated Timeline: Project timeline mapping out key operational steps.
- ​Organization and Budget Details: Breakdown of partner roles and an itemized narrative justifying the budget line items.
- ​Supplementary Attachments: Full project plan/proposal or a detailed meeting agenda.
​Application Process
​Applications must be submitted via the dedicated portal: Visit
- ​Account Creation: First-time users must register and click "Create your password" well ahead of the deadline.
- ​Initiate Application: Click the "Start A New Independent Medical Education Application" button.
- ​Specify Grant Details: Within the application fields, you must select "Yes" for the question "Competitive Grant?".
- ​Select Area of Interest: Choose "Oncology - Breast - IME" as the Primary Area of Interest.
- ​Select Program Name: Choose "2026 INT Breast Cancer IME" as the Competitive Grant Program Name.
- ​Upload and Submit: Upload your finalized 15-page PDF proposal in the General RFP Submission field and complete all online forms.
​Tips to Increase Your Chances
- ​Address Both Pillars Equally: Your proposal will not be competitive if it only focuses on genomic science. You must dedicate equal strategic design to communication training and shared decision-making models.
- ​Explore AI-Enabled Tools: Pfizer explicitly notes interest in projects exploring the responsible use of AI-enabled learning tools, such as interactive case simulations, personalized learning pathways, or virtual practice dialogues.
- ​Focus on Actionable Metrics: Design a robust evaluation plan. Incorporating a control group or comparing outcomes against baseline data will heavily strengthen your proposal during internal review.
- ​Review Core Terms Early: Modifications to Pfizer's standard grant agreements are not reviewed unless there is a direct conflict with applicable local laws. Share the core terms with your institution's legal counsel prior to submission to ensure compliance.
​Common Mistakes to Avoid
- ​Submitting Late: The deadline is absolute: July 20, 2026, at 23:59 EST. Applications submitted even a minute late will be automatically cancelled without review.
- ​Exceeding the Page Limit: Going over the 15-page limit (excluding references) will result in administrative rejection.
- ​Including General Operational Costs as Line Items: General running costs like legal fees, insurance, heating, and lighting must be wrapped into the 28% institutional overhead percentage, not listed as individual line items.
- ​Seeking Asset Funding: Independent Medical Education grants cannot be used to purchase therapeutic prescription or non-prescription assets.
​Application Timeline
[19 MAY 2026: RFP Release] ──► [20 JUL 2026: Submission Deadline] ──► [SEP 2026: Award Notification] ──► [15 NOV 2026: Executed Copy/IRB Deadline] ──► [NOV 2026: Project Start] ──► [MAY 2028: Project End]
(Note: Selected projects must return an executed copy of the Agreement, Protocol, and IRB/IEC documentation by November 15, 2026, to guarantee funding activation).
​Deadline
- ​July 20, 2026 (11:59 p.m. Eastern Standard Time / GMT -5)
​FAQs
​Q: What educational formats are preferred under this RFP?
A: Pfizer considers a wide range of formats, including case-based workshops, modular virtual curricula, virtual molecular tumor board simulations, blended learning, train-the-trainer models, podcasts, and webinars.
​Q: Can a medical practice group apply if they are independent?
A: No. Grants are restricted to recognized organizations and cannot be awarded to independent medical practice groups that lack formal affiliation with a hospital, academic institution, or professional society.
​Q: Who can I contact if I have specific questions about this genomic mBC proposal?
A: Technical issues should be handled via the "Technical Questions" link in CyberGrants. For programmatic inquiries regarding the RFP, email the Grant Officer, Nicola Fenderico (nicola.fenderico@pfizer.com), with the subject line "Advancing Genomic Competence and Patient Centred Care in Metastatic Breast Cancer".
​Official Link(s)
​Final Thoughts
​The Pfizer Independent Medical Education Grant offers a premier avenue for global healthcare organizations to redefine how genomic results are communicated in oncology. By funding up to ten high-impact programs, Pfizer is actively investing in a future where clinicians possess both the biological expertise to interpret deep molecular reports and the communication skills to navigate patient uncertainty. If your institution has a clear vision for improving shared decision-making in metastatic breast cancer care, construct a precise, 15-page, dual-pillar proposal and submit it before the July 20, 2026 deadline.
Leave a Comments
Login to comment
No comments yet.